Loading people...
Fiona MacLaughlin is a Vice President at Johnson and Johnson Innovation JJDC, Inc., where she focuses on strategic venture investments in the life sciences sector from London, United Kingdom. With over 20 years of industry experience, she previously served as a Director of Healthcare Investments at INKEF Capital, leading pharmaceutical and medical technology investments across Europe. Her earlier career includes venture investment roles at Advent Life Sciences and translational funding work at the Wellcome Trust, alongside operational positions at the Almac Group. MacLaughlin has held board director or observer seats at several biotechnology startups, including AviadoBio, Nucleome Therapeutics, SparingVision, and Arrakis Therapeutics. A qualified pharmacist, she earned a PhD in drug delivery systems from Nottingham University. Her current focus centers on funding early-stage therapeutics, medical devices, and drug delivery technologies to advance European biotechnology initiatives.
Fiona MacLaughlin is a distinguished Principal at Johnson & Johnson Innovation, a division dedicated to accelerating scientific discovery and commercialization by collaborating with entrepreneurs, startups, and academic institutions. In her pivotal role, Fiona is instrumental in sourcing, evaluating, and executing strategic investments across the vast landscape of healthcare and life sciences. Her work directly contributes to Johnson & Johnson's mission of improving global health outcomes by identifying and supporting the next generation of medical breakthroughs.
Fiona's investment focus areas are broad yet strategically aligned with Johnson & Johnson's core businesses. She actively seeks opportunities in pharmaceuticals, encompassing novel drug discovery and development platforms, as well as medical devices, where she looks for innovative technologies that can transform patient care. Additionally, her purview extends to consumer health solutions, digital health, and other emerging areas that promise significant impact. She is particularly interested in companies that demonstrate strong scientific foundations, clear unmet medical needs, and scalable business models, often engaging with ventures from their early stages through to significant growth.
Before her tenure at Johnson & Johnson Innovation, Fiona MacLaughlin built a robust career background marked by a deep understanding of both scientific innovation and venture capital. Her experience often includes roles that blend scientific rigor with financial acumen, enabling her to critically assess the technical viability and market potential of new technologies. This dual expertise is invaluable in navigating the complex landscape of healthcare investing, where scientific merit must be balanced with commercial strategy. While specific notable investments are often part of confidential portfolio discussions, her contributions are reflected in the diverse and impactful portfolio of companies Johnson & Johnson Innovation supports, which collectively aim to address some of the world's most pressing health challenges.
Fiona's commitment to fostering innovation extends beyond capital deployment. She often works closely with portfolio companies, leveraging Johnson & Johnson's extensive resources, expertise, and global network to help them achieve their milestones. Her strategic insights and collaborative approach make her a key partner for entrepreneurs seeking to bring their transformative ideas to market. Through her work, Fiona MacLaughlin continues to shape the future of healthcare by backing visionary companies and technologies.
Fiona MacLaughlin is a Principal at Johnson & Johnson Innovation, where she focuses on strategic investments in healthcare and life sciences, identifying and supporting innovative companies.
Fiona MacLaughlin invests in a wide range of healthcare and life science areas, including pharmaceuticals, medical devices, consumer health solutions, and digital health, seeking companies with strong scientific foundations and significant potential.
Fiona MacLaughlin works as a Principal at Johnson & Johnson Innovation, a division of Johnson & Johnson dedicated to accelerating scientific discovery and commercialization through strategic collaborations and investments.
